

ABSTRACT

It is intended to provide an antibody efficacious in diagnosing, preventing or treating Alzheimer's disease, DNA encoding the antibody, a method of screening a drug and drugs. The amino acid sequence and
5 the gene sequence of the variable region of an antibody, which specifically recognizes a GM1 ganglioside-bound amyloid β -protein occurring in the early stage of β -amyloid fibril formation, are determined. Based on the data of the amino acid sequence and the gene sequence thus obtained, an antibody is designed.